For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Cerebrolysin
Illustration for Cerebrolysin

THE PEPSRADAR ENCYCLOPEDIA

Cerebrolysin

Neurological clinical research

Research topics · Sources checked 2026-10-04

Read the studies ↓

Cerebrolysin · KEY FACTS

Content updated · how dates work

Saved peptides

What is Cerebrolysin?

Cerebrolysin is a porcine-brain-derived mixture of peptides and amino acids. In CASTA, the confirmatory combined functional outcome after acute ischemic stroke was neutral.

Biological role or research focus

Neurological clinical research.

A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.

Role reference: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗

Names you may encounter

Porcine brain peptide hydrolysate

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Peptide and amino-acid mixture; not one defined molecule
Research focus
Neurological clinical research
Featured evidence
Human randomized trial
Source check
October 4, 2026

Source: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗

Quick answers

Is Cerebrolysin FDA approved?
No. No FDA-approved drug contains Cerebrolysin. Source ↗
Is Cerebrolysin safe?
Cerebrolysin is a brain-derived peptide mixture not approved in the U.S. Stroke trials found no effect on deaths, and a Cochrane review flagged a possible rise in non-fatal serious adverse events. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
Is Cerebrolysin banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
Has the FDA taken action over Cerebrolysin?
Yes. Our records list 2 FDA actions naming it, most recently on November 10, 2021: FDA warning letter to a clinic-based compounder (Guyer Institute) stating Cerebrolysin had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Human research2 Other evidence
StudyTypePopulation / model
CASTA acute ischemic stroke trial (2012)Human randomized trial1,070 patients with acute ischemic stroke.
CARS · upper-limb recovery (2016)Human randomized trialPatients receiving early rehabilitation after stroke; 208 enrolled according to the publication’s full-text record.
Cochrane stroke review · 2023 (2023)Systematic review of randomized trialsSeven eligible trials with 1,773 participants; the review included a related peptide mixture, Cortexin, as well as Cerebrolysin.
Stroke meta-analysis · 2025 (2025)Systematic review of randomized trials14 randomized trials totaling 2,884 patients with acute ischemic stroke.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2012

CASTA acute ischemic stroke trial

What did this publication test, and what did it find?

Population / model
1,070 patients with acute ischemic stroke.
Study design
Randomized placebo-controlled study of intravenous treatment alongside standard care, with 90-day follow-up.
Main finding
The confirmatory combined functional endpoint did not show a significant benefit. A post-hoc analysis suggested a signal in more severely affected participants.
Limits & context
A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.

Source: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗

Human randomized trial · 2016

CARS · upper-limb recovery

What did the rehabilitation-focused trial find?

Population / model
Patients receiving early rehabilitation after stroke; 208 enrolled according to the publication’s full-text record.
Study design
Double-blind placebo comparison; 21-day treatment and standardized rehabilitation, beginning 24–72 hours after stroke. Primary outcome: Action Research Arm Test at day 90.
Main finding
The reported Mann–Whitney estimator for the arm-test outcome was 0.71 (95% CI 0.63–0.79), favoring Cerebrolysin. Premature discontinuation was 3.8%.
How to read it
A Mann–Whitney estimator of 0.71 is not a 71% cure or a 71% reduction in disability.
Limits & context
The authors called this exploratory and requested larger confirmation. Rehabilitation context and an arm-function endpoint differ from mortality outcomes. Read alongside CASTA and the evidence reviews rather than selecting only a favorable result.

Source: CARS · upper-limb recovery · 2016 ↗

Systematic review of randomized trials · 2023

Cochrane stroke review · 2023

What did the broader review conclude about death and serious harms?

Population / model
Seven eligible trials with 1,773 participants; the review included a related peptide mixture, Cortexin, as well as Cerebrolysin.
Study design
Searches through May–June 2022; independent extraction, risk-of-bias assessment, and GRADE evidence ratings.
Main finding
All-cause mortality RR was 0.96 (95% CI 0.65–1.41). For Cerebrolysin, non-fatal serious adverse events had RR 2.39 (95% CI 1.10–5.23), while total serious events did not clearly differ.
How to read it
Mortality, total serious events, and non-fatal serious events are separate endpoints.
Limits & context
Eligibility required treatment started within 48 hours. Missing functional-outcome reporting and risk-of-bias concerns restrict conclusions. The mortality pool contains a related agent; do not attribute every pooled result exclusively to Cerebrolysin.

Source: Cochrane stroke review · 2023 · 2023 ↗

Systematic review of randomized trials · 2025

Stroke meta-analysis · 2025

Does a newer favorable neurological-score result resolve the debate?

Population / model
14 randomized trials totaling 2,884 patients with acute ischemic stroke.
Study design
Pooled neurological-score changes, functional independence, mortality, and harms; RoB 2 and GRADE assessments reported.
Main finding
The abstract reported improved neurological-score change, but functional independence was not statistically significant: RR 1.31 (95% CI 0.90–1.91). Mortality and total serious adverse events also did not clearly differ.
How to read it
A score change does not establish greater independence or survival.
Limits & context
Review eligibility and endpoint definitions differ from Cochrane. The abstract calls hemorrhagic-transformation results nonsignificant despite a confidence interval excluding 1; that inconsistency needs full-text and statistical review. It should not be used as settled evidence of safety or benefit.

Source: Stroke meta-analysis · 2025 · 2025 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

42 registered studies name Cerebrolysin as an intervention; 6 are recruiting or under way, 3 have not started recruiting yet, 19 completed and 14 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic Stroke
NCT07846488 · National Hospital of Acupuncture, Vietnam
Not yet recruitingNot applicable2026-12-01440
Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy
NCT06339411 · Chang Gung Memorial Hospital
Not yet recruitingPhase 22026-09-01100
Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness
NCT04427241 · Konkuk University Medical Center
RecruitingPhase 42023-06-0112
Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU
NCT06052787 · Ain Shams University
CompletedPhase 32023-09-01150
Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy
NCT05821075 · October 6 University
RecruitingPhase 1 / Phase 22023-08-2490
Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study
NCT07043686 · University Medical Centre Ljubljana
RecruitingNot applicable2025-06-1330
Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial
NCT06899464 · Cardinal Stefan Wyszynski University
Not yet recruitingPhase 42025-10-0130
Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study
NCT06897176 · Yonsei University
RecruitingPhase 42025-03-1240

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 42 listed studies.

Search additional PubMed records ↗

Risks & interactions

Cerebrolysin is a brain-derived peptide mixture not approved in the U.S. Stroke trials found no effect on deaths, and a Cochrane review flagged a possible rise in non-fatal serious adverse events.

Human safety data: Trials only

Randomized stroke trials with over a thousand patients report safety data. A Cochrane review found no clear difference in total serious adverse events but more non-fatal serious events. Findings do not cover similarly named products.

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Serious risks

  • Possible increase in non-fatal serious adverse events in acute stroke trials (Cochrane review, moderate certainty)

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Cochrane review: Cerebrolysin for acute ischaemic stroke (2023) ↗ · CASTA acute ischemic stroke trial (2012) ↗ · CARS stroke recovery trial (2016) ↗ · Stroke meta-analysis of 14 randomized trials (2025) ↗

Safety & what remains unknown

Trial tolerability applies to the tested clinical preparation and setting. It does not verify a mixture sold under a similar name.

Source: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗

Evidence boundaries

A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.

Source: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A category lists. An FDA warning letter (2021) stated it had not been nominated for the 503A bulks list. source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named. S0 only applies to substances with no government approval anywhere; Cerebrolysin is reported to be registered as a medicine in some countries outside the US (not verified here), so whether S0 applies is uncertain. Athletes should check with their anti-doping organization. source

FDA actions

  • FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing Cerebrolysin among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
  • FDA warning letter to a clinic-based compounder (Guyer Institute) stating Cerebrolysin had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. (2021-11-10) source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

The selected study concerns adjunctive treatment after acute ischemic stroke, rather than enhancement of cognition in healthy people.

Source: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Biology & proposed mechanism

The mixture is studied for proposed neurobiological effects. A complex preparation cannot be represented by a single amino-acid sequence or atomic molecular structure.

Source: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗

Questions worth asking

  • Can Cerebrolysin have one exact molecular diagram?
  • What material, population, and route were actually studied?
  • A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Can Cerebrolysin have one exact molecular diagram?

No. It is a mixture, so a single atomic drawing would misrepresent the preparation.

Source: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections